TADALAFIL CRYSTAL FORMS
AND PROCESSES FOR PREPARING THEM
FIELD OF THE INVENTION
The invention relates to crystalline forms of tadalafil and methods of their
synthesis.
RELATED APPLICATIONS
This application claims the benefit of U.S. Application Nos. 60/624,412, filed
November 2,2004, and 60/642,216, filed January 7,2005.
BACKGROUND OF THE INVENTION
Tadalafil, (6R-trans>6-(l, 3-benodioxol-5-yl)-213,6,7,12,12a-hexahydro-2-
methyl-pryazino[ 1,2':1,6] pyrido[3,4b]inddle-l,4-dione, is a white crystalline powder.
(CAS# 171596-29-5).
Tadalafil is currently marketed as Cialis. Cialis was developed by Eli Lilly as
a treatment for impotence. In this capacity, it is reported that tadalafil functions by
inhibiting the formation of cyclic guanosine monophosphate (cGMP)-specific
phosphodiesterase type 5 (PDE5). The inhibition of PDE5 presumably lessens
impotence by increasing the amount ofcGMH, resulting in smootn muscle relaxation
and increased blood flow.
Polymorphism, the occurrence of different crystal forms, is a property of some
molecules and molecular complexes. A single molecule, like Tadalafil, may give rise
to a variety of crystalline forms having distinct crystal structures and physical
properties like melting point, x-ray diffraction pattern, infrared absorption fingerprint,
and solid state NMR spectrum. One crystalline form may give rise to thermal
behavior different from that of another crystalline form. Thermal behavior can be
measured in the laboratory by such techniques as capillary melting point,
thermogravimetric analysis ("TGA"), and differential scanning calorimetry ("DSC1),
which have been used to distinguish polymorphic forms.
The difference in the physical properties of different crystalline forms results
from the orientation and intramolecular interactions of adjacent molecules or
complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the
same molecular formula yet having distinct advantageous physical properties
compared to other crystalline forms of the same compound or complex.
One of the most important physical properties of pharmaceutical compounds is
their solubility in aqueous solution, particularly their solubility in the gastric juices of
a patient. For example, where absorption through the gastrointestinal tract is slow, it
is often desirable for a drug that is unstable to conditions in the patient's stomach or
intestine to dissolve slowly so that it does not accumulate in a deleterious
environment Different crystalline forms or polymorphs of the same pharmaceutical
compounds can and reportedly do have different aqueous solubilities.
The discovery of new polymorphic forms of a pharmaceutically useful
compound provides a new opportunity to improve the performance characteristics of a
pharmaceutical product It enlarges the repertoire of materials that a formulation
scientist has available for designing, for example, a pharmaceutical dosage form of a
drug with a targeted release profile or other desired characteristic. There is a need in
the art for polymorphic forms of tadalafil.
Repetition of the procedure described US 5,859,006 results in crystalline
anhydrous tadalafil form I (using MeOH). Crystalline anhydrous tadalafil form I is
characterized by at least one of: an x-ray diffraction pattern with characteristic
reflections at about 7.3°, 10.6°, 12.6°, 14.6°, 18.5°, 21.8°, and 24.3° ± 0.2° 29, or a
DSC thermogram with a single endotherm at about 300°C.
Repetition of the procedure described WO 04/011463 006 results in crystalline
anhydrous tadalafil form V (using Acetic acid). Crystalline anhydrous tadalafil form
V is characterized by an x-ray diffraction pattern with characteristic reflections at
about 8.3°, 15.1°, 18.8°, 19.2°, and 20.3°± 2° 29. The crystalline form maybe further
characterized by a DSC thermogram with two endotherms at about 110°C and at
about 300°C. Tadalafil form V may be further characterized by TGA, showing a
weight loss of about 13% at a temperature of between about 25°C to about 150°C.
Tadalafil form V may be further characterized by Karl-Fisher, showing water content
of less than 1%. The weight loss corresponds to the theoretical value of tadalafil
Acetic acid of 4:1.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a method of preparing crystalline
anhydrous tadalafil Form I by crystallizing it from a solvent selected from the group
consisting of 2-methoxyethanol, absolute ethanol, acetonitrile, L-propanol,
isopropanoi, etnyj acetate, toluene dimethyl sulfoxide ("DMbO"), n-butanol,
chloroform, tetrahydrofuran ('THF') and mixtures thereof.
In yet a further aspect, the present invention provides a method of preparing
crystalline anhydrous tadalafil Form I that includes the steps of dissolving tadalafil in
a solvent selected from the group consisting of Chloroform, methylene chloride, THF,
and acetone; combining this solution with an organic anti-solvent selected from the
group consisting of petroleum ether, cyclohexane, toluene, xylenes, benzene, and
methyl-tert-butyl ether ("MTBE") to obtain a precipitate; and isolating the precipitate.
In another aspect, the present invention provides an anti-solvent crystallization
method of preparing crystalline anhydrous tadalafil Form I comprising the steps of
dissolving tadalafi] in THF; combining the solution with an anti-solvent selected from
the group consisting of petroleum ether, heptane and hexane; adding anti-solvent that
is methanol until a precipitate is obtained; and isolating the precipitate.
In a further aspect, the present invention provides an exhaustive drying
process for preparing anhydrous crystalline tadalafil Form I that comprises dissolving
crystalline tadalafil in an aliphatic ketone selected from the group consisting of
methylethyl ketone, isobutyl ketone and acetone; cooling the solution to obtain a
precipitate; isolating the precipitate; and exhaustively drying the tadalafil at about
45°C to about 90°C to obtain the crystalline form.
In yet another aspect, the present invention provides a process for preparing
anhydrous crystalline tadalafil Form I by dissolving tadalafil in an aliphatic ketone
selected from the group consisting of methylethyl ketone and acetone; cooling the
solution to obtain a precipitate; isolating the precipitate; and exposing it to high
humidity to obtain the crystalline form.
in one aspeci, tae preseni invention provides a crysiamne rorm or taoaiam
Fonn n characterized by an x-ray diffraction pattern with reflections at about 7.6°,
14.0°, 15.2°, 18.0°, and 22.8° ± 2° 20.
In another aspect, the present invention provides a process for preparing
anhydrous crystalline tadalafil Form I comprising exposing one of the group
consisting of crystalline tadalafil Form n methylethyl ketone solvate and crystalline
tadalafil Form n acetone solvate to high humidity to obtain the crystalline form.
In one aspect, the present invention provides crystalline tadalafil Form HI,
characterized by an x-ray diffraction pattern with reflections at about 8.3°, 13.5°, 7.7°,
and 18.4° ±2° 20.
In another aspect, the present invention provides a process for preparing
anhydrous crystalline tadalafil Form I comprising exposing one of the group
consisting of crystalline tadalafil Form HI methylethyl ketone solvate and crystalline
tadalafil Form HI acetone solvate to high humidity to obtain the crystalline form.
In a Anther aspect, the present invention provides an exhaustive drying
process for preparing a mixture of tadalafil Form I and form JH, comprising
exhaustively drying crystalline tadalafil selected from the group consisting of
crystalline tadalafil Form n methylethyl ketone solvate and crystalline tadalafil Form
II at a temperature of between about 506C to about 75°C.
In one aspect, the present invention provides a crystalline form of tadalafil
Form IV, characterized by an x-ray diffraction pattern with reflections at about 7.6°,
10.6°, 15.2°, 18.40,and22.7°±2<'2e.
In yet another aspect, the present invention provides a method of preparing
crystalline tadalafil Form V, including the steps of providing a solution of tadalafil in
acetic acid; cooling the solution until a precipitate is obtained; and isolating the
precipitate.
In a further aspect, the present invention provides a crystalline form of
tadalafil Form VI, characterized by at least one of: an x-ray diffraction pattern with
reflections at about 7.1°, 9.3°, 11.4°, 13.5°, 17.8°, 19.2°, 212° 29, or by an exotherm
in DSC at about 200°C and a melting endotherm at about 300°C.
In a further aspect, the present invention provides a crystalline form of
tadalafil Form VII, characterized by at least one of: an x-ray diffraction pattern with
reflections at about 7.0°, 13.1°, 17.6°, 19.0°, 20.9°, 24.6° 29, or by two endotherms in
DSC: a broad endotherm at about 170°C and a melting endotherm at about 300°C.
In.another aspect, the present invention provides crystalline tadalafil Form
VTU, characterized by an x-ray diffraction pattern with reflections at about 7.2°, 7.6°,
8.2°, 13.3°, 17.6°, 182°, 22.6° ±2° 29.
In a further aspect, the present invention provides a method of preparing
crystalline tadalafil Form VIII, by performing one of the following: heating crystalline
tadalafil form IV at a temperature of between about 50°C to about 70°C to obtain
crystalline tadalafil Form VTQ; or heating crystalline tadalafil Form IV, at a
temperature of between about 40°C to about 70°C to obtain a mixture of crystalline
tadalafil forms, wherein the crystalline forms are Form Vffl and Form I.
In yet another aspect, the present invention provides a method of preparing
crystalline tadalafil Form I by hearing crystalline tadalafil Form IV at a temperature of
between about 40°C to about 80°C to obtain a mixture of crystalline tadalafil forms
VmandL
JtfKJLfcf UljjSUKin'^UIV Off THE JE
Figure I illustrates an x-ray diffraction diagram of anhydrous crystalline tadalafil
Form I.
Figure 2 illustrates an x-ray diffraction diagram of crystalline tadalafil Form II.
Figure 3 illustrates an x-ray diffraction diagram of crystalline tadalafil Form m.
Figure 4 illustrates an x-ray diffraction diagram of crystalline tadalafil Form IV.
Figure 5 illustrates an x-ray diffraction diagram of crystalline tadalafil Form V.
Figure 6 illustrates an x-ray diffraction diagram of crystalline tadalafil Form VI.
Figure 7 illustrates an x-ray diffraction diagram of crystalline tadalafil Form VII.
Figure 8 illustrates an x-ray diffraction diagram of crystalline tadalafil Form VK.
Figure 9 illustrates a DSC thermogram of anhydrous crystalline tadalafil Form I.
Figure 10 illustrates a DSC thermogram of crystalline tadalafil Form II, methylethyl
ketone solvate.
Figure 11 illustrates a DSC thermogram of crystalline tadalafil Form H, acetone
solvate.
Figure 12 illustrates a DSC thermogram of crystalline tadalafil Form ffi, methylethyl
ketone solvate.
Figure 13 illustrates a DSC thermogram of crystalline tadalafil Form ffi, acetone
solvate.
Figure 14 illustrates a DSC thermogram of crystalline tadalafil Form IV.
Figure IS illustrates a DSC thermogram of crystalline tadalafil Form V.
Figure 16 illustrates a DSC thermogram of crystalline tadalafil Form VI.
Figure 17 illustrates a DSC thermogram of crystalline tadalafil Form VII.
Figure 18 illustrates a DSC thermogram of crystalline tadalafil Form VIEl,
Mgure w illustrates a TUA thermogram of crystalline tadalalil Form 11, methylethyl
ketone solvate.
Figure 20 illustrates a TGA thermogram of crystalline tadalafil Form II, acetone
solvate.
Figure 21 illustrates a TGA thermogram of crystalline tadalafil Form m, methylethyl
ketone solvate.
Figure 22 illustrates a TGA thermogram of crystalline tadalafil Form in, acetone
solvate.
Figure 23 illustrates a TGA thennogram of crystalline tadalafil Form TV.
Figure 24 illustrates a TGA thermogram of crystalline tadalafil Form V.
Figure 25 illustrates a TGA thennogram of crystalline tadalafil Form VI.
Figure 26 illustrates a TGA thermogram of crystalline tadalafil Form VII.
Figure 27 illustrates a TGA thennogram of crystalline tadalafil Form V1H.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides novel crystalline forms of (6R-trans)-6-(l, 3-
benzodioxol-5-yl}-2,3,6,7,12,12a-hexahydro-2-methyl-pryazino[ 1,2': 1,6]
pyrido[3,4b]indolc-l,4-dione. The novel crystalline forms of tadalafil have been
designated Forms n, HI, TV, VI, VII, and VIE. The present invention further provides
methods of making each crystalline form and methods of making crystalline forms I
and V of tadalafil.
By the crystallization processes of this invention, each of the novel crystal
forms of tadalafil can he obtained substantially free from other crystal forms. This
invention also provides crystallization processes, especially in the case of Form ffl,
wim respect 10 rorms u ana uu, ana forms i ana 111, m wmcn a mixture 01 two lorras
can be obtained in the crystallization.
The term "anti-solvent" means a liquid that, when added to a solution of
tadalafil in a solvent, induces precipitation of tadalafil. Precipitation of tadalafil is
induced by the anti-solvent when addition of the anti-solvent causes tadalafil to
precipitate from the solution more rapidly or to a greater extent than tadalafil
precipitates from a solution containing an equal concentration of tadalafil in the same
solvent when the solution is maintained under the same conditions for the same period
of time but without adding the anti-solvent. In other words, the solubility, at a
particular temperature, of tadalafil in the combination of solvent and anti-solvent is
less than that in the solvent alone. Precipitation can be perceived visually as a
clouding of the solution or formation of distinct particles of tadalafil suspended in or
on the surface of the solution, or collected on the walls or at the bottom of the vessel
containing the solution.
The term "lower alcohol" refers to an alcohol containing three or less carbons.
The term "% final volume" as used in reference to anti-solvents means the
liquid volume of the anti-solvent added to the tadalafil solution as compared to the
total liquid volume Of the solvent and anti-solvent, or in the case of the addition of a
first and second anti-solvent, the volume of the second anti-solvent as compared with
the total liquid volume of solvent, first anti-solvent, and second anti-solvent.
The term "room temperature" refers to ambient temperature of from about
10°C to about 30°C, preferably from about 18°C to about 28°C, more preferably from
about 20°C to about 25°C, most preferably from about 21°C to about 23°C.
The term "hot" refers to a temperature of at least above 20°C from the starting
temperature of the reaction mixture.
AS useo aerem, tne term "exhaustively dry" as used in aescnomg processes
for obtaining crystalline tadalafil Form I, refers to drying a sample of crystalline
tadalafil for a time sufficient to effect conversion of the crystalline form to Form I,
typically at least about 3 hours and preferably for about 24 hours.
As used herein, the terms "exhaustively drying" and "exhaustively dried" refer
to both a process for obtaining crystalline tadalafil Form I, by exhaustively drying
previously obtained crystalline tadalafil either Form IE or Form m, and also to an
additional step in the process for obtaining crystalline tadalafil Form II or Form HI,
which can be performed to obtain crystalline tadalafil Form I.
As used herein, the term "slurry" refers to a thin mixture of a liquid and a
finely divided substance, such as any form of crystalline tadalafil.
As used herein, the term "high humidity" refers to an atmosphere in which the
relative humidity is no less than about 80% and is preferably about 100%.
As used herein, the term "relative humidity" refers to the ratio of the amount
of water vapor in the air at a specific temperature to the maximum amount that the air
could hold at that temperature, expressed as a percentage.
As used herein, the term "aliphatic ketone" refers to an organic chemical
compound having the general structure RjC(0)R2 wherein RI and R2 are,
independently, linear or branched alkyl groups having from one to four carbon atoms.
As used herein, the term "exposure time" refers to a period of time sufficient
to effect conversion of crystalline tadalafil to crystalline tadalafil Form I. The
exposure time is typically a period of at least about three days, and preferably a period
of about seven days.
ns usou uerein, uie term • suoscantiauy tree or', in reierence 10 me crystajune
forms H, HI, IV, VI, VH and Vffl refers to crystalline forms having a purity of above
95%, preferably above 99%.
In one embodiment of the invention, crystalline anhydrous tadalafil Form I can
be prepared by a single solvent crystallization method, or by an anti-solvent
crystallization method. In the first step of each method> a solution of tadalafil is
provided. The tadalafil solution can be provided by any convenient means, for
example, by adding tadalafil with solvent to a suitable vessel, as determined by one
skilled in the art, and heating. Possible methods of heating include sand baths, oil
baths, and preferably water baths.
XI
In one embodiment, the present invention provides a method of preparing
crystalline anhydrous tadalafil Form I by crystallizing it from a solvent selected from
the group consisting of 2-methoxyethanol, absolute ethanoi, acetonitrilc, 1-propanol,
isopropanol, ethyl acetate, toluene containing dimethyl sulfoxide ("DMSO"), nbutanol,
chloroform, tetrahvdrofuran ("THF") and mixtures thereof.
In another embodiment, the present invention provides a single solvent
crystallization method for obtaining crystalline anhydrous tadalafil Form I,
comprising the steps of dissolving tadalafil in a solvent selected from the group
consisting of absolute ethanoi, 1-propanol, isopropanol, 2-methoxyethanol,
acetonitrile and mixtures thereof, at a temperature of from about 60°C to about
120°C; cooling the solution until a precipitate is obtained; and isolating the
precipitate. Preferably, the tadalafil is dissolved at a temperature of about 83°C.
Preferably, the solution is cooled to a temperature of below about 30°C and above
about 10°C, more preferably to about room temperature.
impending on tne concentration ot tne proviaea solution ana tne
crystallization temperature of the solution, a holding time, or crystallization time,
which is the time in which the precipitate is obtained, can be employed. Preferably,
the holding time is for about 24 hours or more. Cooling can optionally be performed
in steps, for example, cooling the tadalafil solution to room temperature and later
cooling further to about 10°C. Suitable methods of isolation of the precipitate include
ccntrifugation and decanting and preferably filtration.
In another embodiment, the present invention provides a single solvent
crystallization method for obtaining crystalline anhydrous tadalafil Form I comprising
the steps of dissolving tadalafil in a solvent selected from the group consisting of
ethyl acetate, toluene containing about DMSO, n-butanol, methanol, chloroform, THF
and mixtures thereof; cooling the solution until a precipitate is obtained; and isolating
the precipitate. Preferably, when the solvent is DMSO, its concentration is of about
0.5% to about 5% by volume. Preferably, the tadalafil is dissolved at reflux
temperature. Preferably, the solution is cooled to a temperature of between about 0°C
to about room temperature. Cooling can optionally be performed in steps, for
example, cooling the solution to about room temperature and later further cooling it to
about 0°C in an ice bath for about 1 hour to complete precipitation.
In another embodiment, the present invention provides a process for preparing
anhydrous tadalafil Form I by an anti-solvent crystallization method. The method
comprises dissolving tadalafil in an organic solvent selected from the group consisting
of chloroform, methylene chloride, THF, and acetone; combining the solution with an
organic anti-solvent selected from the group consisting of petroleum ether,
cyclohexane, toluene, xylenes, benzene, hexane, heptane, octane and MTBE, to obtain
a precipitate; and isolating the precipitate. Preferable solvent-anti-solvent
comrnnanons include cniorotorm and one ot me groups consisting ot petroleum etner,
preferably at about 40% final volume, toluene, preferably at about 73% final volume,
xylenes, preferably at about 70% final volume or benzene, preferably at about 70%
final volume. Additional preferable combinations of solvent and anti-solvent include
methylene chloride and cyclohexane, preferably at about 40% final volume, and hot
acetone and MTBE, preferably at about 50% final volume.
In another embodiment, the present invention provides a process for preparing
crystalline anhydrous tadalafil Form I by an anti-solvent crystallization method using
a combination of first and second anti-solvents. The process compnses dissolving
tadalafil in THF; combining the solution with an anti-solvent selected from the group
consisting of petroleum ether, heptane and hexane; adding an anti-solvent that is
methanol until obtaining a precipitate; and isolating the precipitate. Preferably, the
isolation is by filtration. Preferably, after the combination the petroleum ether is
about 96% volume. Preferably, the final volume of methanol is. about 23%.
In another embodiment, crystalline anhydrous tadalafil Form I, can be
produced by an exhaustive drying method. The method comprises dissolving tadalafil
in on aliphatic ketone selected from the group consisting of mcthylothyl ketone,
isobutyl ketone or acetone; cooling the solution to obtain a precipitate; isolating the
precipitate; and exhaustively drying it at a temperature of about 45°C to about 90°C to
obtain the crystalline form. Preferably, the solution is cooled to about room
temperature, and can optionally be further cooled to a temperature not less than about
10°C, to complete precipitation. Preferably, the precipitated crystalline tadalafil is
isolated by filtration. Preferably, the drying occurs at a temperature of about 65°C.
Preferably, the drying is for about 24 hours. Preferably, the drying is under
atmospheric pressure.
In yet another embodiment, crystalline anhydrous tadalafii form 1 can be
produced in a high humidity atmosphere. The process comprises providing a solution
of tadalafil in an aliphatic ketone selected from the group consisting of methylethyl
ketone and acetone; cooling the solution to obtain a precipitate; isolating the
precipitate; and exposing the precipitate to high humidity to obtain the crystalline
form. Preferably, the solution is cooled to about room temperature, and can
optionally be further cooled to a temperature not less than about 10°C, to complete
precipitation. Preferably, the precipitated crystalline tadalafil is isolated by filtration.
Preferably, the high humidity is a relative humidity greater than about 80%, more
preferably a relative humidity of about 100%. Preferably, the precipitate is exposed
to high humidity at about room temperature.
hi another embodiment, the present invention provides novel crystalline forms
of tadalafil which can exist as ketonates. Crystalline tadalafil Form n and crystalline
tadalafil Form HI can exist as ketonates, wherein the ketone can be, for example,
acetone or methylethyl ketone.
la another embodiment, the present invention provides a novel crystalline
form of tadalafil Form n characterized by an x-ray diffraction pattern with
characteristic reflections at about 7.6°, 14.0°, 15.2°, 18.0°, and 22.8° ± 2° 20. The
crystalline form may be a ketone solvate. The ketone solvate may be metbylethyl
ketone solvate or acetone solvate. The crystalline form may be further characterized
by two endotherms in DSC at about 105-115°C and at about 300*C. Tadalafil form II
Methylethyl ketone solvate may be further characterized by TGA, showing a weight
loss of about 15-16% at a temperature of about 100°C. Tadalafil form n Methylethyl
ketone solvate may bo further characterized by Karl-Fisher, showing water content of
less than 1%. Tadalafil form H acetone solvate may be further characterized by TGA,
saovrag a weignt loss ot about iu-1:>% at a temperature ot below aoout .uinj. i ne
weight losses correspond to the theoretical value of tadalafil Methylethyl ketooe
solvate and tadalafil acetone solvatc of 1:1 ratio. Figure 2 depicts a characteristic x--
ray diffraction pattern of crystalline tadalafil Form II. The x-ray diffraction diagram
of Form n is insensitive to the identity of the ketone forming the ketone solvate.
Figures 10 and 19 depict DSC and TGA thermograms corresponding to crystalline
tadalafil Form n methyletbyl ketone solvate, respectively. Figures 11 and 20 depict a
DSC and TGA thermograms corresponding to crystalline tadalafil Form n acetone
ketone solvate, respectively.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form n by a single solvent crystallization method. The method
comprises dissolving tadalafil in a ketone solvent selected from the group consisting
of methylethyl ketone or acetone at a temperature of about 45 °C to about 83°C;
cooling the solution until a precipitate is obtained; and isolating the precipitate:
Preferably, the tadalafil is dissolved at a temperature of about 83°C. Preferably, the
solution is cooled to a temperature of between about 0°C to about 25°C, more
preferably to a temperature of about 10°C.
A holding time can be employed during the cooling. Depending on the
concentration of the provided solution and the crystallization temperature of the
solution, a holding time, or crystallization time, which is the time in which the
precipitate is obtained, can be employed. Preferably, the holding time is for about 24
hours or more. Cooling can optionally be performed in steps, for example, cooling
the tadalafil solution to room temperature and later cooling further to about 10°C.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form n by using an anti-solvent crystallization method. The
method compnses dissolving tadalafil ui methylethyl ketone, combuung me solution
with an anti-solvent selected from the group consisting of petroleum ether,
cyciohexane, or MTBE, until a precipitate is obtained, and isolating the precipitate.
Preferably, the anti-solvent comprises about 50% of the final volume.
Tadalafil form I can be also obtained by drying crystalline Tadalafil form n
ketone solvate at a temperature of between about 40°C to about 90°C. Preferably, the
drying is at a temperature of about 50°C. Preferably, the drying is for at least 2 days.
Preferably, the drying is under atmospheric pressure
In yet another embodiment, crystalline tadalafil Form n, methylethyl ketone
solvate or crystalline tadalafil Form n, acetone solvate, can be used to produce
crystalline anhydrous tadalafil Form I in a high humidity atmosphere. The method
comprises exposing crystalline tadalafil selected from the group consisting of
crystalline tadalafil Form n, methylethyl ketone solvate and crystalline tadalafii Form
II, acetone solvate to high humidity until obtaining the crystalline form. Preferably,
the high humidity is a relative humidity greater than about 80%, most preferably a
relative humidity of about 100%. Preferably, the exposure is at about room
temperature.
In another embodiment, the present invention provides a novel crystalline
form of tadalafil Form ffl, ketone solvate characterized by an x-ray diffraction pattern
with characteristic reflections at about 8.3°, 13.5°, 7.7°, and 18.4°±2°28. The
crystalline form may be further characterized by two endotherms in DSC at about 80-
90°C and at about 300°C. The crystalline form may be a ketone solvate. The ketone
solvate may be methylethyl ketone solvate or acetone solvate. Tadalafil form in
Methylethyl ketone may be further characterized by TGA, showing a weight loss of
about 4-5% at a temperature of about 808C. Tadalafil form HI Methylethyl ketone
solvate may DC runner cnaractenzeo oy Kari-r isner, snowing water content or less
than 1%. The weight loss corresponds to the theoretical value of tadalafil Methylethyl
ketone solvate of 4:1 ratio. Tadalafil form HI acetone solvate may be further
characterized by TGA, showing a weight loss of about 2-3% at a temperature of
between about 25°C to about 140°C. Tadalafil form III acetone solvate may be further
characterized by Karl-Fisher, showing water content of less than 1%. The weight loss
corresponds to the theoretical value of tadalafil aceone solvate of 5:1 ratio. Figure 3
depicts a representative x-ray diffraction pattern of crystalline tadalafil Form EL The
x-ray diffraction diagram of Form in is insensitive to the identity of the ketone
forming the ketone solvate. Figures 12 and 21 depict representative DSC and TGA
thermograms of crystalline tadalafil Form in methylethyl ketone solvate, respectively.
Figures 13 and 22 depict representative DSC and TGA thermograms of crystalline
tadalafil Form in, acetone solvate, respectively.
hi another embodiment, the present invention provides a process for preparing
a mixture of tadalafil Form H and Form HI, ketone solvates by drying crystalline
tadalafil Form II, ketone solvate at a temperature of about 50°C to about 80°C for
about 0.5 to about 6 hours. Preferably, the crystalline form is dried under vacuum.
Preferably, the crystalline form is dried to a temperature of about 65°C. Preferably,
the crystalline form is dried for about 3 hours. A mixture of tadalafil Form n and
Form ni methylethyl ketone solvate, can also be obtained by drying tadalafil Form n,
methylethyl ketone solvate at a temperature of about 45°C to about 70°C for about 0.5
to about 5 hours. Preferably, the crystalline form is dried at a temperature of about
65 °C. Preferably, the crystalline form is dried under vacuum. Preferably, the
crystalline form is dried for about 2 hours.
in a prererred embodiment, crystalline tadalafil form ill, acetone soivate can
be obtained by drying crystalline tadaUfil Form n, acetone soivate at a temperature of
about 45°C to about 70°C for about 0.5 to about 5 hours. Preferably, the crystalline
form is dried to a temperature of about 65°C. Preferably, the crystalline form is dried
under vacuum. Preferably, the crystalline form is dried for about 3 hours,
Drying of Tadalafil form II ketone soivate should be controlled properly in
order to get the desired crystal form. Drying of Tadalafil Ketone soivate form II by
vacuum will give form m, while drying under atmospheric pressure will resulted in
the formation of form I. Time of drying should be sufficient for complete conversion
to the desired crystal form.
In yet another embodiment, crystalline tadalafit Form HI, methylethyl ketone
soivate or crystalline tadalafil Form HI, acetone soivate can be used to produce
crystalline anhydrous tadalafil Form I in a high humidity atmosphere. The method
comprises exposing crystalline tadalafil selected from the group consisting of
crystalline tadalafil Form ID, methylethyl ketone soivate and crystalline tadalafil
Form m, acetone soivate to high humidity. Preferably, the high humidity is a relative
humidity greater than about 80%, most preferably a relative humidity of about 100%.
Preferably, the exposure is at about room temperature.
In another embodiment, crystalline tadalafil Form II, methylethyl ketone
soivate or crystalline tadalafil Form II, acetone soivate can be used to produce a
mixture of crystalline anhydrous tadalafil Form I and crystalline tadalafil form III by
an exhaustive drying method. The method comprises drying the crystalline tadalafil
selected from the group consisting of crystalline tadalafil Form n, methylethyl ketone
soivate and crystalline tadalafil Form II, acetone soivate, at a temperature of between
about 50°C to about 75°C. Preferably, the drying is under atmospheric pressure
rreieraoiy, me drying is at a temperature 01 about 65UC. Prererably, the drying is tor
at least about 24 hours.
In another embodiment, the present invention provides a novel crystal form of
tadalafil Form IV, characterized by an x-ray diffraction pattern with characteristic
reflections at about 7.6°, 10.6°, 15.2°, 18.4°, and 22.7° ±2° 26. The crystalline form
may be further characterized by two endothenns in DSC at about 110-115°C and at
about 300°C. Tadalafil form IV may be further characterized by TGA, showing a
weight loss of about 11-16% at a temperature of between about 25°C to about 130°C.
Figure 4 depicts a characteristic x-ray diffraction pattern of crystalline tadalafil Form
IV. Figures 14 and 23 depict characteristic DSC and TGA thermograms of crystalline
tadalafil Form IV, respectively.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form IV by a single solvent crystallization method, comprising
the steps of dissolving tadalafil in methylene chloride; cooling the solution until a
precipitate is obtained; and isolating the precipitate. Preferably, the dissolving step is
at about reflux temperature. Preferably, the solution is cooled to a temperature of
between about 0°C to about room temperature. Preferably, the solution is first cooled
to about room temperature and then is cooled to about 0°C in an ice bath for about 1
hoar to complete precipitation.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form IV, by an anti-solvent crystallization process. The process
comprises providing a solution of tadalafil in methylene chloride; combining the
solution with an anti-solvent that is petroleum ether until a precipitate is formed; and
isolating the precipitate. Preferably, the dissolving step is at about reflux temperature.
Preferably, the petroleum ether is about 30% from the final volume.
Tadalafil form II, form ffl, and form IV are all characterized by an
endothermic peak by DSC at about 80- 120°C, and by a melting endotherm at about
300°C.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form V by a single solvent crystallization method. The process
comprises dissolving tadalafil in acetic acid; cooling the solution until a precipitate is
obtained; and isolating the precipitate. Preferably, tadalafil is dissolved at about
reflux temperature. Preferably, the cooling is to a temperature of between about room
temperature to about 0°C. Preferably, the solution is first cooled to about room
temperature and then is cooled to about 0°C in an ice bath for about 1 hour to
complete precipitation.
In another embodiment, the present invention provides a crystalline anhydrous
form of tadalafil Form VI, characterized by at least one of: an x-ray diffraction pattern
with reflections at about 7.1°, 9.3°, 11.4°, 13.5°, 17.8°, 19.2°, 21.2° 29, or by an
exotherm in DSC at about 200°C and a melting endotherm at about 300°C. Tadalafil
form VI may be further characterized by TGA, showing a weight loss of less than 1%.
Figure 6 depicts a representative x-ray diffraction pattern of crystalline tadalafil Form
VI. Figures 16 and 28 depict representative DSC and TGA thermograms of
crystalline tadalafil Form VI, respectively.
In another embodiment, the present invention provides a process for preparing
Crystalline anhydrous tadalafil Form VI by using a single solvent method. The
method comprises sturrying methanol and tadalafil Form IV until obtaining a
precipitate; and isolating the precipitate. Preferably, the tadalafil is isolated by
filtration. Preferably, the isolated precipitate is dried at a temperature of about 40°C
to about /tru, more preterably at a temperature of about 6.5-u(J, under vacuum, for
about 3 hours.
In another embodiment, the present invention provides a crystalline form of
tadalafil Form VEI, toluene solvate characterized by at least one of: an x-ray
diffraction pattern with reflections at about 7.0°, 13.1°, 17.6°, 19.0°, 20.9°, 24.6° 20,
or by two endotherms in DSC: a broad endotherm at about 170°C and a melting
endotherm at about 300°C. The crystalline form may be a toluene solvate. Tadalafil
form Vfl may be further characterized by TGA, showing a weight loss of about 5-6%
at a temperature of about 80°C. Tadalafil form VII may be further characterized by
Karl-Fisher, showing water content of less than 1%. Figure 7 depicts a representative
X-ray diffraction pattern of crystalline tadalafil Form VIT. Figures 17 and 26 depict
representative DSC and TGA thermograms of crystalline tadalafil Form VII,
respectively.
In yet another aspect, the present invention provides a method of preparing
crystalline tadalafil Form VII including the steps of providing a slurry of toluene and
tadalafil, wherein the tadalafil is selected from the group of crystalline forms
consisting of crystalline tadalafil Form IV, crystalline tadalafil Form V, and
crystalline tadalafil Form II until a precipitate is obtained; and isolating the
precipitate. Preferably, the isolation is by filtration. Preferably, the isolated
precipitate is dried at about 65°C.
In another embodiment, the present invention provides crystalline tadalafil
Form Vffl, dichloromethane solvate, characterized by an x-ray diffraction pattern with
reflections at about 7.2°, 7.6°, 8.2°, 13.3°, 17.6°, 18.2°, 22.6° ±2° 29. The crystalline
form may be dichloromethane solvate. The crystalline form may be further
characterized by two endotherms at about 100°C and at about 300eC. Tadalafil form
VIH may be further characterized by TGA, showing a weight loss of about 7-9%.
Figure 8 depicts a representative x-ray diffraction pattern of crystalline tadalafil Form
VTH. Figures 18 and 27 depict representative DSC and TGA thermograms,
respectively, of crystalline tadalafil Form VHI.
In another embodiment, the present invention provides a process for preparing
crystalline tadalafil Form Vffl, dichloromethane solvate by heating. In this method,
crystalline tadalafil form IV can either be heated to a temperature of between about
50°C to about 70°G, preferably to about 65°G, preferably under vacuum, to obtain
crystalline tadalafil Form VIE, dichloromethane solvate, or can be heated to about a
temperature of between about 40°C to about 70°C, preferably to about 60°C,
preferably under atmospheric pressure, to obtain a mixture of crystalline tadalafil
forms, wherein the forms are crystalline anhydrous tadalafil Form I, and crystalline
tadalafil Form Yin, dichloromethane solvate.
In yet another embodiment, the present invention provides a method of
preparing crystalline tadalafil Form I, by heating crystalline tadalafil Form IV at about
a temperature of between about 40°C to about 80°C, preferably to about 60°C, to
obtain a mixture of crystalline tadalafil forms, wherein the crystalline forms are Form
Vin and Form L Preferably, heating is under atmospheric pressure.
Another embodiment of the invention encompasses crystalline forms II, HI,
IV, VI, Vn and Vffl of tadalafil substantially free of crystalline Form I.
Crystalline forms II, ffl, IV, VI, VH and Vffl of tadalafil may be obtained with
a particle size distribution, of particles having d(0.9), of about 200ji o about 600u.
The particles size distribution of Tadalafil crystalline forms of the present invention
may vary by changing experimental parameters, such as cooling rate, and speed of
agitation.
The particles size distribution of Form I may be of about 200^1 to about 600u,
after milling.
X-ray diffraction data was obtained with a Scintag, variable goniometer, Cutube,
solid state detector, using a round standard aluminum sample holder with round
zero background. Scanning parameters: Range 2-40° 26: continuous scan at a rate of
3°/min.
DSC data was obtained with a DSC8216, Mettler Toledo. The sample weight
was about 3-Smg, and the heating (scan) rate was about WC/mia. The lid of the
crucible had 3 holes in it.
TGA data was obtained using a Mettler TG50 using standard alumina pan.
The sample weight was 7-15mg, and the heating (scan) rate was about lO'/min.
A cold room thermostatted between 10°C and 30°C was used in several of the
following examples. The temperature was changed according to the needs and
objectives of the experiment.
EXAMPLES
Preparation of Tadalafil Crystal Form I
Example 1
Tadalafil (5.01 g) was added to aaErlenmeyer flask with2-methoxyethanol
(104 ml) and heated in a water bath at about 83°C until dissolved. The solution was
cooled to room temperature, and after about 24 hours, was further cooled in a cold
room about 24 hours. The precipitate was collected by filtration and dried in a
vacuum oven for about 3 hours at about 65°C. Tadalafil form I was obtained. Loss on
drying ("LOD") by TGA was 0.6%.
Example 2
Tadalafil (5.07 g) was added to an Erlenmeyer flask with absolute ethanol
(950 ml) and heated in a water bath at about 83°C until dissolved. The solution was
cooled to room temperature, and after about 24 hours, was further cooled in a cold
room for about 24 hours. The precipitate was collected by filtration and dried in a
vacuum oven for about 3 hours at about 65°C. Tadalafil form I was obtained. LOD
byTGAwasO.3%.
Example 3
Tadalafil (5.07 g) was added to an Erlenmeyer flask with acetonitrile (250 ml)
and heated in a water bath at about 83°C until dissolved. The solution was cooled to
room temperature, and after about 24 hours, was further cooled in a cold room for
about 24 hours. The precipitate was collected by filtration and dried in a vacuum
oven for about 3 hours at about 65°C. Tadalafil form I was obtained.
Example 4
Tadalafil (5.14 g) was added to an Erlenmeyer flask with l-propanol (1 L) and
heated in a water bath at about 83°C until dissolved. The solution was cooled to room
temperature, and after about 24 hours, was further cooled in a cold room for about 24
hours. The precipitate was collected by filtration and dried in a vacuum oven for
about 3 hours at about 65°C.
Example 5
Tadalafil (4.18 g) was added to an Erlenmeyer flask with isopropanol (1 L)
and heated in a water bath at about 83°C until dissolved. The solution was cooled to
room temperature, and after about 24 hours, was further cooled in a cold room for
about 24 hours. The precipitate was collected by filtration and dried in a vacuum
oven for about 3 hours at about 65°C.
Example 6
Tadalafil (5.0 g) was stirred in ethyl acetate (950 ml) and heated to reflux
temperature. The solution was left overnight to crystallize, and was further cooled in
an ice bath for about 1 hour. The precipitate was then collected by filtration.
Example 7
Tadalafil (5.0 g) was stirred in toluene (160 ml) and DMSO (4 ml) and heated
to reflux temperature. The solution was left overnight to crystallize, and was further
cooled in an ice bath for about 1 hour. The precipitate was then collected by filtration
Example 8
Tadalafil (5.0 g) was stirred in n-butanol (300 ml) and heated to reflux
temperature. The solution was left overnight to crystallize, and was further cooled in
an ice bath for about 1 hour. The precipitate was then collected by filtration.
gx ample j>
Tadalafil (5.0 g) was stirred in methanol (850 ml) and heated to reflux
temperature. The solution was left overnight to crystallize, and was further cooled in
an ice bath for about 1 hour. The precipitate was then collected by filtration.
25
Kyampie m
TadaJafil (5.0 g) was stirred in chloroform (225 ml) and heated to reflux
temperature. The solution was left overnight to crystallize, and was further cooled in
an ice bath for about 1 hour. The precipitate was then collected by filtration.
Example 11
Tadalafil (5.0 g) was stirred in THF (150 ml) and heated to reflux temperature.
The solution was left overnight to crystallize, and was further cooled in an ice bath for
about 1 hour. The precipitate was then collected by filtration.
Example 12
Tadalafil (5.0 g) was dissolved in chloroform (300 ml). Petroleum ether 40-60
(200 ml) was added to the solution, and the resulting precipitate was collected by
filtration.
Example 13
Tadalafil (5.0 g) was dissolved in methylene chloride (300 ml). Cyclohexane
(200 ml) was added to the solution, and the resulting precipitate was collected by
filtration.
Example 14
Tadalafil (5.0 g) was dissolved in THF (20 ml). Petroleum ether 40-60 (500
ml) was added to the solution, followed by an addition of methanol (150 mis). The
resulting precipitate was then collected by filtration.
Example IS
Tadalafil (5.0 g) was dissolved in chloroform (300 ml). Toluene (800 ml) was
then added to the solution, and the resulting precipitate was collected by filtration.
Example 16
Tadalafil (5.0 g) was dissolved in chloroform (300 ml). Mixture of Xylenes
(620 ml) were then added to the solution, and the resulting precipitate was collected
by filtration.
Example 17
Tadalafil (5.0 g) was dissolved in chloroform (300 ml). Benzene (700 ml) was
then added to the solution, and the resulting precipitate was collected by filtration.
Example 18
Tadalafil (5.0 g) was dissolved in acetone (400 ml) at 55°C. MTBE (400 ml)
was added to the solution, and the resulting precipitate was collected by filtration.
Example 19
Tadalafil (5.0 g) was dissolved in methylethyl ketone (400 ml) at 80°C.
Petroleum ether 40-60 (400 ml) was added to the solution, and the resulting
precipitate was collected by filtration. The sample was then dried at 65°C overnight
under atmospheric pressure to yield a mixture of Form I and solvated Form IH.
Example 20
Methylethyl ketone (750 ml) was added to a 1L Erlemneyer flask and heated
to 80°C in a water bath. Tadalafil (12.4 g) was slowly added An additional sinall
amount of methylethyl kctone was added to insure total dissolution. The solution was
removed from the heating bath. It crystallized, was stirred overnight, and filtered the
following day. The sample was then dried at 65°C overnight under atmospheric
pressure to yield a mixture of Form I and solvated Form IE.
Example 21
Tadalafil (5.0 g) was dissolved in hot methylethyl ketone (400 ml). Petroleum
ether 40-60 (400 ml) was added and the resulting precipitate was filtered. The sample
was held at 50°C for 7 days to yield Form I.
Example 22
Tadalafil (5,0 g) was dissolved in hot methylethyl ketone (400 ml). Petroleum
ether 40-60 (400 ml) was added to the solution, and the resulting precipitate was
filtered. The sample was analyzed by XRD and by TGA and found to contain
Tadalafil form n MethylEthyl Ketone solvate. The sample was held at room
temperature at 100% humidity for 7 days to yield Form L
Example 23
Methylethyl ketone (750 ml) was added to a 1L Erlenmeyer flask and heated
in a water bath. Tadalafil (12.4 g) was slowly added An additional small amount of
methylethyl ketone was added to insure total dissolution. The solution was removed
from the heating bath. It crystallized, was stirred overnight, and was filtered the
following day. The sample was identified by XRD and by TGA analyses to contain
torm II Metnyl JbthyJ Ketone soivate. 1'he sample was held at room temperature at
100% relative humidity for 7 days to yield Form I.
Example 24
Tadalafil (5.09 g) was heated with acetone (326 ml) at 83°C in a water bath
until dissolution was complete. The solution was removed from the water bath and
cooled to room temperature. After 24 hours of standing, the sample was placed in a
cold room for 24 hours, filtered, and dried at 65°C for 24 hours.
Example 25
Tadalafil (5.09 g) was heated with acetone (326 ml) at 83°C in a water bath
until dissolution was complete. The solution was removed from the water bam and
cooled to room temperature. After 24 hours of standing, the sample was placed in a
cold room for 24 hours, and then filtered. The sample was held for 3 days at room
temperature in 100% relative humidity to yield Form I.
Preparation of Tadalafil Crystal Form II
Example 26
Tadalafil (5.14 g) was added to an Erlenmeyer flask with methylethyl ketone
(346 ml) and heated in a water bath at about 83°C until dissolved. The solution was
cooled to room temperature, and after about 24 hours, was further cooled in a cold
room for about 24 hours. The resulting precipitate was collected by filtration. Water
content by Karl Fischer ("KF") was 0.46%. Tadalafil form H was obtained.
Example 27
Tadalafil (5.09 g) was added to an Erlenmeyer flask with acetone (326 ml) and
heated in a water bath at about 83°C until dissolved. The solution was cooled to room
temperature, and after about 24 hours, was further cooled in a cold room at about 10-
30°C for about 24 hours. The resulting precipitate was collected by filtration.
Tadalafil form II was obtained.
Example 28
Tadalafil (5.0 g) was dissolved in methylethyl ketone (400 ml) at 80°C.
Petroleum ether (400 ml) was added to the solution, and the resulting precipitate was
collected by filtration. Tadalafil form II was obtained.
Example 29
Tadalafil (5.0 g) was dissolved in hot methylethyl ketone (400 ml).
Cyclohexane (400 ml) was added to the solution, and the resulting precipitate was
collected by filtration. Tadalafil form n was obtained.
Example 30
Tadalafil (5.0 g) was dissolved in hot methylethyl ketone (400 ml). MTBE
(400 ml) was added to the solution, and the resulting precipitate was collected by
filtration. Tadalafil form n was obtained. Water content by KF was 0.11%.
Preparation of Tadalafil Crystal Form IH
Example 31
Tadalafil prepared according to Example 26 was dried at about 65°C under
vacuum for about 3 hours; resulting in a mixture of Forms II and HI.
Example 32
Tadalafil prepared according to Example 27 was dried at about 65°C under
vacuum for about 3 hours, resulting in a mixture of Forms II and HL
Example 33
Tadalafil methylethyl ketone solvate Form n was heated at atmospheric
pressure at about 65°C for about 2 hours, resulting in a mixture of Forms I and HI.
Tadalafil acetone solvate Form II was heated at 65°C under vacuum for about
3 hours, resulting in Tadalafil Form HI. Water content by KF was 0.4%.
Preparation of Tadalafil Crystal Form TV
Example 35
Tadalafil (5.0 g) was stirred in methylene chloride (450 ml) and heated to
reflux temperature. It was left overnight to crystallize, and then further cooled in an
ice bath for about 1 hour to complete precipitation. The precipitate was then filtered.
Tadalafil form IV was obtained. Water content by KF was 0.2 1%.
Example 36
Tadalafil (5.0 g) was dissolved in methylene chloride (700 ml). 40-60
petroleum ether (300 ml) was added to the solution, and the resulting precipitate was
collected by filtration. Tadalafil form IV was obtained. Water content by KF was
0.38%.
Preparation of Tqdalafil Crystal Form V
Example 37
Tadalafil (5.0 g) was stirred in acetic acid (50 ml) and heated to reflux
temperature. It was left overnight to crystallize, and then further cooled in an ice bath
for 1 hour. The resulting precipitate was then collected by filtration. Water content
by KF was 0.20%. Tadalafil form V was obtained. See TGA thermogram in Figure
Preparation of Tadalafil Crystal Form VI
Example 38
Tadalafil Form IV (2;0g) was slurried overnight in methanol (15nu) and
filtered the following day. The sample was dried at 65°C under vacuum for 3h.
Tadalafil form VI was obtained. Water content by KF was less than about 1%.
Preparation of Tadalafil Crvst
Example 39
Tadalafil Form IV (2.0g) was slurried overnight in toluene (20ml) and filtered
the following day. The sample was dried at 65°C under vacuum for 3h. Tadalafil
form VH was obtained.
Example 40
Tadalafil Form V (2.0g) was slurricd in toluene (20ml) overnight, and filtered
the following day. The sample was dried at 65°C under vacuum for 3h. Tadalafil
form VII was obtained.
Ex ample 41
Tadalafil Form n (2.0g) was shirried overnight in toluene (20ml) and filtered
the following day. The sample was dried at 65°C under vacuum for 3h. TadalafiJ
form VII was obtained.
Preparation of Tadalafil Crystal Form VD1
Epmp}e42
Tadalafil dichloromethane solvate Form IV (2.0g) was heated at 65 °C under
vacuum. Tadalafil form VIII was obtained.
Example 43
Tadalafil dichloromethane solvate Form IV (0.5 g) was heated at 60°C under
atmospheric pressure to obtain a mixture of crystalline tadalafil forms Form I and
Form VIII.

What is claimed is:
1. A process for preparing crystalline tadalafil form I comprising crystallizing it
from a solvent selected from the group consisting of: 2-methoxyethanol,
absolute ethanol, acetonitrile, 1-propanol, isopropanol, ethyl acetate, toluene
and dimethyl sulfoxide ("DMSO"), n-butanol, chloroform, tetrahydrofuran
("THF") and mixtures thereof.
2. A process for preparing the crystalline tadalafil form I, comprising the steps
of:
a) dissolving tadalafil in a solvent selected from the group consisting of 2-
methoxyethanol, absolute ethanol, acetonitrile, 1-propanol, isopropanol,
and mixtures thereof, at a temperature of at least about 60°C to about
120°C to obtain a solution;
b) cooling the tadalafil solution of step a) until a precipitate is obtained; and
c) isolating the precipitate of step b).
3. The process of claim 1, wherein the solution in step b) is cooled to a
temperature below about 30°C and above about 10°C.
4. The process of claim 1, wherein the solution in step b) is cooled to about room
temperature.
5. A process for preparing the crystalline tadalafil form I, comprising the steps
of:
a) dissolving tadalafil in a solvent selected from the group consisting of
ethyl acetate, toluene containing about DMSO, n-butanol, methanol,
chloroform, THF and mixtures thereof to obtain a solution;
34
o) cooung the tadaiatii solution of step a) until a precipitate is obtained; and
c) isolating the precipitate of step b) to obtain crystalline tadalafil.
6. The process of claim 5, wherein the tadalafil in step a) is dissolved at reflux
temperature.
7. The process of claim 5, wherein the solution in step b) is cooled to a
temperature below about room temperature and above about 0°C.
8. A process for preparing the crystalline tadalafil form I, comprising the steps
. of:
a) dissolving tadalafil in a solvent selected from the group consisting of
chloroform, methylene chloride, THF, and acetone to obtain a solution;
b) combining the solution of step a) with an anti-solvent selected from the
group consisting of petroleum ether, cyclohexane, toluene, xylenes,
benzene, hexane, heptane, octane, and MTBE, until a precipitate is
obtained; and
c) isolating the precipitate of step b) to obtain crystalline tadalafil.
9. The process of claim 8 wherein the solvent of step a) is chloroform and the
anti-solvent of step b) is selected from the group consisting of: petroleum
ether, wherein the petroleum ether is about 40% final volume, toluene,
wherein the toluene is about 73% final volume, the xylenes, wherein the
xylenes are about 70% final volume, and benzene, wherein benzene is about
70% final volume.
10. The process of claim 8 wherein the solvent of step a) is THF and the antisolvent
comprises first and second anti-solvents, wherein the first anti-solvent
is petroleum ether, wherein the petroleum ether is about 96% volume after
comDinanon witti tne taflaiatn solution, and wnerein me second ana-solvent is
methanol, wherein methanol is about 23% final volume.
11. The process of claim 8 wherein the solvent of step a) is methylene chloride
and the anti-solvent of step b) is cyelohexane, wherein the cyclohexane is
about 40% final volume.
12. The process of claim 8 wherein the solvent of step a) is acetone and the antisolvent
of step b) is MTBE, wherein the MTBE is about 50% final volume.
13. A process for preparing the crystalline tadalafil form I, comprising the steps
Of:
a) dissolving tadalafil in THF to obtain a solution;
b) combining the solution of step a) with an anti solvent selected from the
group consisting of: petroleum ether, heptane and hexane;
c) adding an anti-solvent that is methanol until a precipitate is obtained; and
d) isolating the precipitate of step c) to obtain crystalline tadalafil.
14. A process for preparing the crystalline tadalafil form I, comprising the steps
of:
a) dissolving tadalafil in an aliphatic ketone selected from the group
consisting of mcthylethyl ketone, isobutyl ketone or acetone to obtain a
solution;
b) cooling the solution until a precipitate is obtained; and
c) drying the precipitate of step c) at a temperature of about 45°C to about
90°C to obtain crystalline tadalafil.
15. The process of claim 14, wherein the solution is cooled to room temperature.
16. The process of claim 15, wherein the solution is further cooled to a
temperature of less than about 10°C.
me process. 01 claim 14, wnerein tne precipitate in step c; is onca 10 acorn
65°C.
18. The process of claim 14, wherein the precipitate in step c) is dried under
atmospheric pressure,
19. A process for preparing the crystalline tadalafil form I, comprising the steps
of:
a) dissolving tadalafil in an aliphatic ketone selected from the group
consisting of methylethyl ketone and acetone to obtain a solution;
b) cooling the solution until a precipitate is obtained;
c) isolation the precipitate; and
d) exposing the precipitate to high humidity to obtain crystalline tadalafil.
20. The process of claim 19, wherein the solution in step b) is cooled to about
room temperature.
21. The process of claim 20, wherein the solution is further cooled to a
temperature of less than about 10°C.
22. A crystalline form of tadalafil (Form n) characterized by x-ray
reflections at about 7.6°, 14.0°, 15.2", 18.0°, and 22.8° ± 2" 29.
23. The crystalline tadalafil of claim 22 having an x-ray diffraction diagram
substantially as depicted in Figure 2.
24. The crystalline form of claim 22, characterized by two endotherms in DSC at
about 105-115°C and at about 300°C.
25. The crystalline form of claim 22, characterized by TGA, showing a weight
loss of about 10-15% at a temperature of below about 120°C.
26. The crystalline tadalafil of claim 22, wherein the crystalline tadalafil is a
ketone solvate.
me urysiaiune laaaiani or ciaim /o wnerein me Ketone soivate is>
methylcthyl ketone solvate.
28. The crystalline tadalafil of claim 26 wherein the ketone solvate is
acetone solvate.
29. A process for preparing the crystalline form of tadalafil of claim 22
comprising the steps of:
a) providing a solution of tadalafil in a solvent selected from the group
consisting of methylethyl ketone and acetone, at a temperature of about
45°C to about 83°C;
b) cooling the solution of step a) until a precipitate is obtained; and
c) isolating the precipitate of step b) to obtain the crystalline tadalafil of
claim 22.
30. The process of claim 29, wherein tadalafil in step a) is provided at about 83°C.
31. The process of claim 29, wherein the solution in step b) is cooled to a
temperature below about O'C and above about 25°C.
32. The process of claim 31, wherein the solution in step b) is cooled to about
10°C.
33. A process for preparing the crystalline form of tadalafil of claim 22
comprising the steps of:
a) dissolving tadalafil in methylethyl ketone to obtain a solution;
b) combining the solution of step a) with an anti-solvent selected from the
group consisting of petroleum ether, cyclohexane, and MTBE, until a
precipitate is obtained; and
c) isolating the precipitate of step b) to obtain crystalline tadalafil.
34. A process for preparing crystalline tadalafil Forni i comprising trie steps ol
drying crystalline Tadalafil form II ketone solvate at a temperature of about
40°C to about 90°C.
35. The process of claim 34, wherein the drying is for at least 2 days.
36. The process of claim 34, wherein the drying is under atmospheric pressure.
37. The process of claim 34, wherein the drying is at a temperature of about 50°C.
38. A process for preparing crystalline tadalafil Form I comprising the steps of
exposing crystalline tadalafil selected from the group consisting of crystalline
tadalafil Form H, methylethyl ketone solvate and crystalline tadalafil Form n,
acetone solvate to high humidity.
39. A crystalline form of tadalafil (Form HI) characterized by x-ray reflections at
about 8.3°, 13.5°, 7.7°, and 18.4° ± 2° 29.
40. The crystalline form of tadalafil of claim 39 having an x-ray diffraction
diagram substantially as depicted in Figure 3.
41. The crystalline form of tadalafil of claim 39, characterized by two endotherms
in DSC at about 80-90°C and at about 300°C.
42. The crystalline form of tadalafil of claim 39, characterized by TQA, showing a
weight loss of about 4-5% at a temperature of about 80°C.
43. The crystalline tadalafil of claim 39, wherein the crystalline tadalafil is a
ketone solvate.
44. The crystalline tadalafil of claim 43, wherein the ketone solvate is methyletbyl
ketone solvate.
45. The crystalline tadalafil of claim 43, wherein the ketone solvate is acetone
solvate.
46. A process for preparing the crystalline form of tadalafil of claim 3y
comprising one of the following:
a) drying crystalline tadalafil Form n, at a temperature of about 50°C to
about 80°C under vacuum for about 0.5 to about 6 hours until obtaining
a mixture of crystalline tadalafil Form n and Form HI; or
b) drying the tadalafil methylethyl ketone solvate Form n, at about 45°C to
about 70°C under vacuum for about 0.5 to about 5 hours to obtain a
mixture of crystalline tadalafil Form n and Form TQ-t or
c) drying the tadalafil acetone solvate Form n, at about 45°C to about 70°C
under vacuum for about 0.5 to about 5 hours to obtain crystalline tadalafil,
designated Form III.
47. The process of claim 46, wherein the drying in a), b) or c) is at a temperature
of about 65°C.
48. The process of claim 46, wherein the drying in a), b) or c) is under vacuum.
49. A process for preparing the crystalline tadalafil Form I comprising exposing
crystalline tadalafil selected from the group consisting of crystalline tadalafil
Form HI, methylethyl ketone solvate and crystalline tadalafil Form m, acetone
solvate to high humidity.
50. A process for preparing a mixture of crystalline tadalafil Form I and
crystalline tadalafil form m comprising the steps of drying the crystalline
tadalafil selected from the group consisting of crystalline tadalafil Form H,
methylethyl ketone solvate and crystalline tadalafil Form II, acetone solvate, at
a temperature of between about 50°C to about 75°C.
51. The process of claim 50, wherein the drying under atmospheric pressure.
52. The process of claim 50, wherein the drying is to a temperature of about 65°C.
53. A crystalline torm ol tadaiani (tform IV) charactenzea by x-ray renecuons at
about 7,6°, 10.6°, 15.2°, 18.4°, and 22.7° ± 2° 29.
54. The crystalline form of tadalafil of claim 53 having an x-ray diffraction
diagram substantially as depicted in Figure 4.
55. The crystalline form of tadalafil of claim 53, characterized by two endotherms
in DSC at about 110-115°C and at about 300°C.
56. The crystalline form of tadalafil of claim 53, characterized by TGA, showing a
weight loss of about 11-16%.
57. A process for preparing the crystalline form of tadalafil of claim 53
comprising the steps of:
a) dissolving tadalafil in raethylene chloride to obtain a solution;
b) cooling the solution of step a), until a precipitate is obtained; and
c) isolating die precipitate of step c) to obtain the crystalline tadalafil..
58. The process of claim 57, wherein the dissolving in step a) is at about reflux
temperature.
59. The process of claim 57, wherein the solution in step b) is cooled to a
temperature of between about 0°C to about room temperature.
60. A process for preparing the crystalline form of tadalafil of claim 53
comprising the steps of:
a) dissolving tadalafil in methylene chloride to obtain a solution;
b) combining the solution of step a) with petroleum ether; and
c) isolating the precipitate of step b) to obtain crystalline tadalafil.
61. The process of claim 60, wherein the dissolving in step a) is at about reflux
temperature.
t2. A process tor preparing tne crystalline lorm v oi taoaiaru compnsing ine steps
of:
a) dissolving tadalafil in acetic acid to obtain a solution;
b) cooling the solution of step a) to obtain a precipitate; and
c) isolating the precipitate of step b) to obtain the crystalline tadalafil.
63. The process of claim 62, wherein the dissolving in step a) is at about reflux
temperature.
64. The process of claim 62, wherein the cooling in step b) is to a temperature of
between about room temperature to about 0°C.
65. A crystalline form of tadalafil (Form VI) characterized by at least one of:
a) x-ray reflections at about 7.1°, 9.3°, 11.4°, 13.5°, 17.8°, 19.2°, 21.2° 29, or
b) an exothcrm in DSC at about 200°C and a melting endotherm at about
300°C.
66. The crystalline form of tadalafil of claim 65, having an x-ray diffraction
diagram substantially as depicted in Figure 6.
67. The crystalline form of tadalafil of claim 65, having a DSC thermogram
substantially as depicted in Figure 16.
68. The crystalline form of tadalafil of claim 65, characterized by TGA, showing a
weight loss of less than 1%.
69. A process for preparing the crystalline form of tadalafil of claim 65
compnsing the steps of:
a) providing a slurry of methanol and crystalline tadalafil Form IV; and
b) isolating the tadalafil from step a) to obtain crystalline tadalafil.
70. The process of claim 69, wherein the isolated form is further dried at a
temperature of about 40PC to about 70°C under vacuum.
71. i ne process 01 claim to, wnerem toe isolated crystalline tadalafil 15 dried at a
temperature of about 65°C.
72. The process of claim 69, wherein the drying is for about 3 hours.
73. A crystalline form of tadalafil (Form VU) characterized by at least one of the
following:
a) x-ray reflections at about 7.0°, 13.1°, 17.6°, 19.0°, 20.9°, 24.6° 20; or
b) two endotherms in DSC at about 170°C and about 300°C
74. The crystalline form of tadalafil of claim 73, having an x-ray diffraction
diagram substantially as depicted in Figure 7.
75. The crystalline form of tadalafil of claim 73, having a DSC thermogram
substantially as depicted in Figure 17.
76. The crystalline form of tadalafil of claim 73, wherein the crystalline form is a
toluene solvate.
77. A process for preparing the crystalline form of tadnlafil of claim 73
comprising the steps of:
a) slurrying tadalafil in toluene, wherein the tadalafil is selected from
a group of crystalline forms consisting of: Form TV, Form V, and Form
II, until a precipitate is obtained; and
b) isolating the precipitate of step a) to obtain crystalline tadalafil.
78. The process of claim 77, wherein the isolated form is further dried at about
65°C under vacuum.
79. The process of claim 78, wherein the drying is for about 3 hours.
80. A crystalline form of tadalafil (Form VIII) characterized by x-ray reflections
at about 7.2°, 7.6°, 8.2°, 13.3°, 17.6°, 18.2°, 22.6° ± 2* 29.
si. i ne crystalline xonn 01 tauaiaui 01 ciaim an naving an x-ray cniirauuon
diagram substantially as depicted in Figure 8.
82. The crystalline form of claim 80, characterized by two endotherms in DSC at
about 100°C and about 300°C.
83. The crystalline form of tadalafil of claim 80 wherein the crystalline form is a
dicnloromethane solvate
84. A process for preparing the crystalline form of tadalafil of claim 80
comprising one of the following steps:
a) heating crystalline tadalafil Form IV to a temperature of about 50°C to
about 70°C; or
b) heating crystalline tadalafil Form IV to a temperature of about 40°C to
about 70"C to obtain a mixture of crystalline tadalafil Form I and Form VHI.
85. The process of claim 84, wherein the crystalline tadalafil Form IV in a) is
heated to a temperature of about 65°C.
86. The process of claim 84, wherein the heating in a) is under vacuum.
87. The process of ciaim 84, wherein the crystalline tadalafil Form IV in b) is
heated to a temperature of about 60°C.
88. The process of claim 84, wherein the heating in b) is under atmospheric
pressure.
89. A process for preparing crystalline anhydrous tadalafil Form I, wherein
crystalline tadalafil Form IV is heated to a temperature of about 40°C to about
80QC, to obtain a mixture of crystalline tadalafil foims, wherein the crystalline
forms are denominated Form I and Form VHT.
90. The process of claim 89, wherein the heating is to a temperature of about
60°C.
91. The process of claim 89, wherein the heating is under atmospheric pressure.